We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical features of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis: a new aspect of paraneoplastic autoimmune condition.
- Authors
Urai, Shin; Iguchi, Genzo; Kanie, Keitaro; Bando, Hironori; Yamamoto, Masaaki; Oi, Yuka; Kashitani, Yuya; Iida, Keiji; Kanzawa, Maki; Fukuoka, Hidenori; Takahashi, Michiko; Shintani, Yasushi; Ogawa, Wataru; Takahashi, Yutaka
- Abstract
The pathogenesis of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis was gradually revealed as cases emerged. Our comprehensive analysis, including all reported cases, identified a new instance of anti-PIT-1 hypophysitis postimmune checkpoint inhibitor therapy. All 9 patients exhibited extremely low growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) levels; 2 had a slightly atrophic pituitary gland; 4 had thymoma, and 5 had malignant neoplasms of diffuse large B-cell lymphoma (DLBCL) and other origins. Patients with thymoma showed multiple autoimmune diseases. HLA-A*24:02 and/or A*02:06 were present in six and DR53 in 5 cases analyzed. High anti-PIT-1 antibody titers and ectopic PIT-1 expression in the cytosol and nucleus of the tumor tissues were observed in patients with thymoma or DLBCL, whereas it was exclusively observed in the nuclei of a bladder cancer patient. These findings provide new insights into the pathophysiology of paraneoplastic autoimmune hypophysitis.
- Subjects
ENDOCRINOLOGY; PATHOGENESIS; PARANEOPLASTIC syndromes; IMMUNE checkpoint inhibitors; CANCER immunotherapy; ANTINEOPLASTIC agents
- Publication
European Journal of Endocrinology, 2024, Vol 190, Issue 1, pK1
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1093/ejendo/lvad179